Trial Profile
Open-label, single arm, phase II study for evaluation of complete response rate at surgery after NEOadjuvant treatment with SUnitinib and docetaxel in patients with newly diagnosed large operable or locally advanced breast cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2011
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms NEOSU
- 17 Aug 2011 New trial record